Description
TransGLYCIT contains all material needed to perform glycan remodeling of 1 mg human IgG with the G0, G1, G2 or G2S2 glycoform.
TransGLYCIT contains all material needed to perform glycan remodeling of 1 mg human IgG with the G0, G1, G2 or G2S2 glycoform.
Label | |
---|---|
Application | |
Unit Definition | TransGLYCIT transglycosylates ≥95% of human IgG1 as measured by LC-MS. |
Inhibitors | |
Buffer Compatibility | |
Substrates | |
Specificity | GlycINATOR hydrolyzes the B-1,4-linkage between core GlcNAc residues on all IgG Fc-glycoforms., TransINATOR catalyzes the transglycosylation of an oxazoline modified glycoform (G0, G1, G2 or G2S2) onto the exposed GlcNAc. |
Digestion Site | |
Product Composition | |
Source/Origin | Cloned from S. pyogenes Produced in E. coli (His-tagged) 92 kDa |
Product Group | |
Reaction Conditions | Deglycosylation (GlycINATOR): 60 min incubation at RT, Transglycosylation (TransINATOR): 45 min incubation at RT, The protocol may need optimization depending on the antibody |
Unfortunately no, the enzyme requires trimming of the Fc-glycan using GlycINATOR to enable access to the core fucose substrate.
Yes, the transglycosylation reaction can be performed on all subclasses of human IgG. The reaction is somewhat slower on IgG2 and longer incubation times may be necessary to obtain over 95% transglycosylation.
No, TransGLYCIT is based on IgG specific enzymes and will only transglycosylate IgG.
The TransGLYCIT platform is developed for transglycosylation of human IgG.
GlycINATOR is an IgG specific endoglycosidase that hydrolyzes complex, hybrid and high mannonse type glycans on the conserved Fc site on IgG.